In NSCLC, tumor‐associated CD8+ TRM cells express JAML, which binds to the cancer‐derived CXADR, activating the TRM cells. Higher numbers of CD8+ TRM cells and JAML expression are positively correlated with better patient prognosis. The gene discussed is CD8A; the disease is cancer.